Blend is a biotechnology company creating novel medicines including miniaturized biologic drug conjugates (mBDC) that are designed to be precisely directed to solid tumors and overcome the biological barriers that limit the effectiveness of many cancer medicines today.

Through our Pentarin™ platform, Blend is developing cancer therapies with an unprecedented ability to penetrate deep into the cancer tissue and selectively attack the cancer cells with novel therapeutic targeting.

[Read more]